In 2025, Yanagisawa et al. [2, 3] described a patient with ALK-positive NSCLC and controlled type 2 diabetes mellitus that developed DKA 3 months after initiating lorlatinib; this patient was notably absent of islet cell autoantibodies. Here, ALK is linked to non-small cell lung carcinoma.